Why the study?
To compare the effects of two combination therapies (ACE inhibitor plus thiazide-like diuretic plus metformin vs ACE inhibitor plus moxonidine plus metformin) on blood pressure, arterial stiffness, central aortic pressure, and metabolic parameters in hypertensive patients with prediabetes.
Does the combination of perindopril, moxonidine, and metformin improve blood pressure profiles, vascular stiffness, and metabolic parameters compared to perindopril, indapamide, and metformin in patients with hypertension and prediabetes?
RCT (n=80)
Envelope method
Does the combination of perindopril, moxonidine, and metformin improve blood pressure profiles, vascular stiffness, and metabolic parameters compared to perindopril, indapamide, and metformin in patients with hypertension and prediabetes?
A combination of perindopril, moxonidine, and metformin may offer superior vasoprotective and metabolic benefits compared to a perindopril, indapamide, and metformin regimen in patients with hypertension and prediabetes.
Supports perindopril-moxonidine-metformin over perindopril-indapamide-metformin in hypertensive prediabetes; extends RCT evidence for combined vascular-metabolic benefits.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Skibitsky et al. (2021) conducted an RCT in Hypertension and prediabetes (n=80). Perindopril, moxonidine, and metformin vs. Perindopril, indapamide, and metformin was evaluated on 24-hour blood pressure profile, arterial stiffness, central aortic pressure, and metabolic parameters.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: